Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636761 | 0.83 | P2RX7 (0.51) | P2RX7GPR119KDM4EGRM1 | |
| SCHEMBL1636897 | 0.82 | P2RX7 (0.52) | P2RX7GPR119KDM4EMEN1KMT2A | |
| SCHEMBL1636703 | 0.81 | P2RX7 (0.49) | P2RX7 | |
| SCHEMBL1636701 | 0.80 | P2RX7 (0.47) | P2RX7GPR119 | |
| SCHEMBL1637704 | 0.79 | P2RX7 (0.48) | P2RX7GPR119 | |
| SCHEMBL1635930 | 0.77 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL1636147 | 0.77 | P2RX7 (0.50) | P2RX7GPR119 | |
| SCHEMBL1636699 | 0.77 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL1636672 | 0.77 | P2RX7 (0.50) | P2RX7GPR119 | |
| SCHEMBL1636744 | 0.75 | P2RX7 (0.52) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| CN-101679291-A | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885GPR119 69/4885KDM4E 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.